|
1
|
Chen DS: Hepatocellular carcinoma in
taiwan. Hepatol Res. 2 Suppl 37:S101–S105. 2007. View Article : Google Scholar
|
|
2
|
Hung TH, Liang CM, Hsu CN, Tai WC, Tsai
KL, Ku MK, Wang JW, Tseng KL, Yuan LT, Nguang SH, et al:
Association between complicated liver cirrhosis and the risk of
hepatocellular carcinoma in taiwan. PLoS one. 12:e01818582017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim GA, Lee HC, Choe J, Kim MJ, Lee MJ,
Chang HS, Bae IY, Kim HK, An J, Shim JH, et al: Association between
non-alcoholic fatty liver disease and cancer incidence rate. J
Hepatol. 2:32294–32298. 2017.
|
|
4
|
Huang YT, Yang HI, Liu J, Lee MH, Freeman
JR and Chen CJ: Mediation analysis of hepatitis b and c in relation
to hepatocellular carcinoma risk. Epidemiology. 27:14–20. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the united states from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tazi el M, Essadi I, M'Rabti H, Touyar A
and Errihani PH: Systemic treatment and targeted therapy in
patients with advanced hepatocellular carcinoma. N Am J Med Sci.
3:167–175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan S, Wang J, Yang Y, Zhang J, Liu H,
Xiao J, Xu Q, Huang X, Xiang B, Zhu S, et al: The prediction of
clinical outcome in hepatocellular carcinoma based on a six-gene
metastasis signature. Clini Cancer Res. 23:289–297. 2017.
View Article : Google Scholar
|
|
8
|
Yu GP, Xiao QY, Shi ZQ, Tang LS, Ma XP,
Zhang LY, Chen HT, Wang WJ, Zhang PY, Ding DL, et al: Genetic
polymorphisms in apoptosis-related genes and the prognosis of
hepatocellular carcinoma. Am J Cancer Res. 5:3249–3259.
2015.PubMed/NCBI
|
|
9
|
Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M,
Liu S, Jiang X, Zheng J, Zhang X and Chen P: Prognostic biomarker
identification through integrating the gene signatures of
hepatocellular carcinoma properties. EbioMedicine. 19:18–30. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song BN and Chu IS: A gene expression
signature of FOXM1 predicts the prognosis of hepatocellular
carcinoma. Exp Mol Med. 50:e4182018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Llovet JM and Bruix J: Testing molecular
therapies in hepatocellular carcinoma: The need for randomized
phase II trials. J Clin Oncol. 27:833–835. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ringelhan M, Pfister D, O'Connor T,
Pikarsky E and Heikenwalder M: The immunology of hepatocellular
carcinoma. Nat Immunol. 19:222–232. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Y, Wang B, Wu J, Zhang C, Zhou Y,
Yang X, Zhou J, Guo W and Fan J: Association of preoperative EpCAM
circulating tumor cells and peripheral treg cell levels with early
recurrence of hepatocellular carcinoma following radical hepatic
resection. BMC Cancer. 16:5062016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang MH, Sun R, Zhou XM, Zhang MY, Lu JB,
Yang Y, Zeng LS, Yang XZ, Shi L, Xiao RW, et al: Epithelial cell
adhesion molecule overexpression regulates epithelial-mesenchymal
transition, stemness and metastasis of nasopharyngeal carcinoma
cells via the PTEN/AKT/mTOR pathway. Cell Death Dis. 9:22018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beer TW, Shepherd P and Theaker JM: Ber
EP4 and epithelial membrane antigen aid distinction of basal cell,
squamous cell and basosquamous carcinomas of the skin.
Histopathology. 37:218–223. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheibani K, Shin SS, Kezirian J and Weiss
LM: Ber-EP4 antibody as a discriminant in the differential
diagnosis of malignant mesothelioma versus adenocarcinoma. Am J
Surg Pathol. 15:779–784. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen YL, Chen PM, Lin PY, Hsiau YT and Chu
PY: ABCG2 overexpression confers poor outcomes in hepatocellular
carcinoma of elderly patients. Anticancer Res. 36:2983–2988.
2016.PubMed/NCBI
|
|
18
|
Yu HC, Hung MH, Chen YL, Chu PY, Wang CY,
Chao TT, Liu CY, Shiau CW and Chen KF: Erlotinib derivative
inhibits hepatocellular carcinoma by targeting CIP2A to reactivate
protein phosphatase 2A. Cell Death Dis. 5:e13592014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maetzel D, Denzel S, Mack B, Canis M, Went
P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M and Gires O:
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell
Biol. 11:162–171. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Litvinov SV, van Driel W, van Rhijn CM,
Bakker HA, van Krieken H, Fleuren GJ and Warnaar SO: Expression of
Ep-CAM in cervical squamous epithelia correlates with an increased
proliferation and the disappearance of markers for terminal
differentiation. Am J Pathol. 148:865–875. 1996.PubMed/NCBI
|
|
21
|
Osta WA, Chen Y, Mikhitarian K, Mitas M,
Salem M, Hannun YA, Cole DJ and Gillanders WE: EpCAM is
overexpressed in breast cancer and is a potential target for breast
cancer gene therapy. Cancer Res. 64:5818–5824. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chaves-Perez A, Mack B, Maetzel D,
Kremling H, Eggert C, Harréus U and Gires O: EpCAM regulates cell
cycle progression via control of cyclin D1 expression. Oncogene.
32:641–650. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamashita T, Budhu A, Forgues M and Wang
XW: Activation of hepatic stem cell marker EpCAM by
Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res.
67:10831–10839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Spizzo G, Went P, Dirnhofer S, Obrist P,
Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R,
et al: High Ep-CAM expression is associated with poor prognosis in
node-positive breast cancer. Breast cancer Res Treat. 86:207–213.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spizzo G, Went P, Dirnhofer S, Obrist P,
Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G and Zeimet
AG: Overexpression of epithelial cell adhesion molecule (Ep-CAM) is
an independent prognostic marker for reduced survival of patients
with epithelial ovarian cancer. Gynecol Oncol. 103:483–488. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stoecklein NH, Siegmund A, Scheunemann P,
Luebke AM, Erbersdobler A, Verde PE, Eisenberger CF, Peiper M,
Rehders A, Esch JS, et al: Ep-CAM expression in squamous cell
carcinoma of the esophagus: A potential therapeutic target and
prognostic marker. BMC Cancer. 6:1652006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmelzer E, Wauthier E and Reid LM: The
phenotypes of pluripotent human hepatic progenitors. Stem Cells.
24:1852–1858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bae JS, Noh SJ, Jang KY, Park HS, Chung
MJ, Park CK and Moon WS: Expression and role of epithelial cell
adhesion molecule in dysplastic nodule and hepatocellular
carcinoma. Int J Oncol. 41:2150–2158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY,
Yeh TS and Lee WC: CD133-positive hepatocellular carcinoma in an
area endemic for hepatitis B virus infection. BMC Cancer.
9:3242009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee
JE, Cho JY, Yoo JE, Choi JS and Park YN: Human hepatocellular
carcinomas with ‘Stemness’-related marker expression: Keratin 19
expression and a poor prognosis. Hepatology. 54:1707–1717. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi
GM, Zhang BH, Wu WZ, Shi YH, Wu B, et al: High expression levels of
putative hepatic stem/progenitor cell biomarkers related to tumour
angiogenesis and poor prognosis of hepatocellular carcinoma. Gut.
59:953–962. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shan YF, Huang YL, Xie YK, Tan YH, Chen
BC, Zhou MT, Shi HQ, Yu ZP, Song QT and Zhang QY: Angiogenesis and
clinicopathologic characteristics in different hepatocellular
carcinoma subtypes defined by EpCAM and α-fetoprotein expression
status. Med Oncol. 28:1012–1016. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamashita T, Forgues M, Wang W, Kim JW, Ye
Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al: EpCAM and
alpha-fetoprotein expression defines novel prognostic subtypes of
hepatocellular carcinoma. Cancer Res. 68:1451–1461. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sung JJ, Noh SJ, Bae JS, Park HS, Jang KY,
Chung MJ and Moon WS: Immunohistochemical expression and clinical
significance of suggested stem cell markers in hepatocellular
carcinoma. J Pathol Transl Med. 50:52–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fong D, Seeber A, Terracciano L, Kasal A,
Mazzoleni G, Lehne F, Gastl G and Spizzo G: Expression of EpCAM(MF)
and EpCAM(MT) variants in human carcinomas. J Clin Pathol.
67:408–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu CJ, Chen PJ, Chen DS, Tseng TC and Kao
JH: Perspectives on dual hepatitis B and C infection in taiwan. J
Formos Med Assoc. 115:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hussain SP, Schwank J, Staib F, Wang XW
and Harris CC: TP53 mutations and hepatocellular carcinoma:
Insights into the etiology and pathogenesis of liver cancer.
Oncogene. 26:2166–2176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vilchez V, Turcios L, Marti F and Gedaly
R: Targeting Wnt/β-catenin pathway in hepatocellular carcinoma
treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi F, Lian S, Wu P and Shen L:
Transarterial chemoembolization with or without microwave ablation
in the treatment of intermediate (BCLC B) hepatocellular carcinoma.
J Clin Oncol. 35:e156352017. View Article : Google Scholar
|
|
40
|
Kimura O, Kondo Y, Kogure T, Kakazu E,
Ninomiya M, Iwata T, Morosawa T and Shimosegawa T: Expression of
EpCAM increases in the Hepatitis B related and the
treatment-resistant hepatocellular carcinoma. BioMed Res Int.
2014:1729132014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seino S, Tsuchiya A, Watanabe Y, Kawata Y,
Kojima Y, Ikarashi S, Yanai H, Nakamura K, Kumaki D, Hirano M, et
al: Clinical outcome of hepatocellular carcinoma can be predicted
by the expression of hepatic progenitor cell markers and serum
tumour markers. Oncotarget. 9:21844–21860. 2018. View Article : Google Scholar : PubMed/NCBI
|
